Targeting signal transduction for disease therapy

Current Opinion in Cell Biology

Volumn 8, Issue 2, 1996, Pages 239-244

  Levitzki, Alexander ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ABS 225; ANTINEOPLASTIC AGENT; BRYOSTATIN; CELL NUCLEUS RECEPTOR; CISPLATIN; CYCLIN DEPENDENT KINASE; DOXORUBICIN; ENZYME INHIBITOR; ETOPOSIDE; FULVESTRANT; GENISTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN FARNESYLTRANSFERASE; PROTEIN TYROSINE KINASE; RAS PROTEIN; RECEPTOR ANTIBODY; TAMOXIFEN; TRANSCRIPTION FACTOR; TYRPHOSTIN; UNCLASSIFIED DRUG; WORTMANNIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; B CELL LEUKEMIA; DRUG DEVELOPMENT; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; INFLAMMATION; NONHUMAN; ONCOGENE; ONCOGENE NEU; PAPILLOMA; PRIORITY JOURNAL; PSORIASIS; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 0029925701     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-0674(96)80071-8     Document Type: Review

References (54)

1. Levitzki A: Signal transduction therapy. Eur J Biochem 1994, 226:1-13.
2. Powis G: Signaling pathways as targets for anticancer drug development. Pharmacol Ther 1994, 62:57-95.
3. Fry DW: Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors. Exp Opin Invest Drugs 1994, 3:577-595.
4. Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino MA Jr, Ullrich A et al.: Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 1991, 11:117-127.
5. Baselga J, Mendelsohn J: Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther 1994, 64:127-154.
6. Yoneda T, Lyall R, Alsine MM, Pearsons PE, Spada AP, Levitzki A, Zilberstein A, Mundy GR: The antiproliferative effects of tyrosine kinase inhibitor tyrphostin on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res 1991, 51:4430-4435.
7. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, DeSolms SJ, Giuliani EA, Gomez RP, Graham SL, Hamilton K et al.: Inhibition of farnesyltransferase induces regression of mammary and salivary carcinoma in ras transgenic mice. Nature Med 1995, 1:792-797. A clear demonstration that an inhibitor of a widespread proto-oncoprotein which participates in many cellular processes can be an effective drug.
8. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leader S, Freedman M, Cohen A, Gazit A et al.: Inhibition of recurrent human pre-B acute lymphoblastic leukemia by Jak-2 tyrosine kinase inhibitor. Nature 1996, 379:645-648. In this study it is shown that AG490 inhibits JAK-2 in pre-B leukemic cells, but does not block any of the other expressed PTKs. JAK-2 is constitutively active in these cells and seems to be the main growth promoter. AG490 causes complete eradication of the human disease engrafted in SCID mice, with no adverse effect on normal blood tissue or any other systemic toxic effects.
9. Asn17 under the control of the Rous sarcoma virus promoter. Expression of this dominant-negative Ras protein resulted in 55-62% inhibition of neointima formation. This is an important example of signal transduction gene therapy.
10. Shore SK, Nabissa PM, Reddy EP: Ribozyme-mediated cleavage of the BCR-ABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity. Oncogene 1993, 8:3183-3188.
11. Choo Y, Sanchez-Garcia I, Klug A: In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence. Nature 1994, 372:642-645. This paper provides the first example of the construction of a vector expressing a zinc-finger DNA-binding protein specific for a unique sequence of an oncogene. When the construct was transfected into BCR-ABL transformed cells, this expressed zinc-finger protein reversed the transformed phenotype.
12. Martiny-Baron G, Marmé D: VEGF mediated tumor angiogenesis: a new target for cancer therapy. Curr Opin Biotechnol 1995, 6:675-680.
13. Levitzki A: Src as a target for anticancer drugs. Anti Cancer Drug Des 1996, in press.
14. Levitzki A, Gazit A: Tyrosine kinases inhibition: an approach to drug development. Science 1995, 267:1782-1788. A comprehensive review of PTK blockers. The review shows that a large variety of pharmacophores was found to be effective in the design of PTK blockers. AG879 a and its analogs are mentioned in this paper, but data are still unpublished.
15. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ: A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 9:1093-1095.
16. Buchdunger E, Trinks U, Mett H, Regenass U, Muller M, Meyer T, McGlynn E, Pinna LA, Traxler P, Lydon NB: 4,5-dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc Natl Acad Sci USA 1994, 91:2334-2338.
17. c-Src may be important for the oncogenic phenotype observed in cells which overexpress EGFR.
18. Uckun FM, Evans WE, Forsyth CJ, Waddick KG, Ahlgren LT, Chelstrom LM, Burkhardt A, Bolen J, Myers DE: Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 1995, 267:886-891. An interesting study which describes the delivery of a non-selective PTK blocker to the target tumor cell by binding it to an antibody raised against an antigen expressed on the tumor cell.
19. Ross RC: The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature 1993, 302:801-809.
20. Kovalenko M, Gazit A, Bohmer A, Rorsman L, Ronnstrand J, Heldin CH, Waltenberger, Bohmer FD, Levitzki A: Selective platelet-derived growth factor receptor kinase blockers reverse cis-transformation. Cancer Res 1994, 54:6106-6114. The most selective PDGF receptor blockers are described. These blockers do not inhibit the vascular endothelial growth factor receptor, Flk-1/KDR, making them suitable as potential blockers of restenosis as they block the proliferation of smooth muscle cells but not of endothelial cells.
21. Bryckaert MC, Eldor A, Gazit A, Osherov N, Gilon C, Fontenay M, Levitzki A, Tobelem G: Inhibition of platelet derived growth factor (PDGF) Induced mitogenic activity by PDGF receptor tyrosine kinase tyrphostin inhibitors. Exp Cell Res 1992, 199:255-261.
22. Golomb G, Fishbein I, Banai S, Mishaly D, Moscovitz D, Gertz A, Gazit A, Levitzki A: Controlled delivery of a tyrphostin inhibits intimal hyperplasia in rat carotid artery injury model. Atherosclerosis 1996, in press. The effective use of a non-selective PTK blocker as an inhibitor of restenosis by localized delivery, using a slow release biocompatible polymer.
23. Elder JT, Fisher GJ, Lindquist PB, Bennet GL, Pittelkow MR, Goffey RJ Jr, Elliysworth L, Derynk R, Voorhees JJ: Overexpression of TGFα in psoriatic epidermis. Science 1989, 243:670-675.
24. Ben-Bassat H, Vardi DV, Gazit A, Klaus SN, Chaouat M, Hartzstark Z, Levitzki A: Tyrphostins suppress the growth of psoriatic keratinocytes. Exp Dermatol 1995, 4:82-84. The first report of the potential use of EGFR blockers as drugs to treat psoriasis.
25. Werness BA, Levine AJ, Howley PM: Association of human Papllloma virus type 16 and 18 with p53. Science 1990, 248:76-79.
26. Dyson N, Howley PM, Munger K, Harlow E: The human Papillomavirus-16 E7 is able to bind the retinoblastoma gene product. Science 1989, 243:934-937.
27. Auewarakul P, Gissmaa L, Cid-Arregui A: Targeted expression of the E6 and E7 oncogenes of human papillomavirus type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors. Mol Cell Biol 1994, 14:8250-8258.
28. Weinstein SL, Gold MR, DeFranco AL: Bacterial lipopolysaccharide stimulates protein tyrosine phosphorylation in macrophages. Proc Natl Acad Sci USA 1991, 88:4148-4156.
29. lyn. J Biol Chem 1993, 268:20725-20727.
30. Novogrodsky A, Vanichkin A, Patya M, Gazit A, Osherov N, Levitzki A: Prevention of LPS-induced lethal toxicity by tyrosine kinase blockers. Science 1994, 264:1319-1322.
31. Vanichkin A, Patya M, Gazit A, Levitzki A, Novogrodsky A: Late administration of lipophylic tyrphostins prevents lipopolysaccharide and E. coli lethal toxicity. J Infect Dis 1996, in press.
32. Ji L, Zhang G, Hirabayashi Y: Tumor necrosis factor alpha increases tyrosine phosphorylation of a 23-kDa nuclear protein in U937 cells through ceramide signaling pathway. Biochem Biophys Res Commun 1995, 215:489-496.
33. Gibbs JB, Oliff A, Kohl N: Farnesyl transferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994, 77:175-178.
34. Bos JL: Ras oncogenes and human cancer. Cancer Res 1989, 49:4682-4689.
35. Segal M, Willumsen BM, Levitzki A: Residues crucial for Ras interaction with GDP-GTP exchangers. Proc Natl Acad Sci USA 1993, 90:5564-5568.
36. Symons M: The Rac and Rho pathways as a source for drug targets for Ras-mediated malignancies. Curr Opin Biotechnol 1995, 6:668-674.
37. Cordon-Cardo C: Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995, 147:545-560.
38. Vesely J, Havlicek L, Strand M, Blow JJ, Donlla-Deana A, Pinna L, Letham DS, Kato J, Detvaud L, Leclerc S et al.: Inhibition of cyclin dependent kinases by purine analogs. Eur J Biochem 1994, 224:771-786.
39. Kitagawa M, Okabe T, Ogino H, Matsumoto H, Suzuki-Takahashi I, Kokubo T, Higashi H, Saitoh S, Taya Y, Yasuda H et al.: Butyrolactone-1, a selective inhibitor of cdk2 and cdc 2 kinase. Oncogene 1993, 8:2425-2432.
40. Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ: Potent inhibition of cdc2 kinase by the flavanoid L86-8275. Biochem Biophys Res Commun 1994, 201:589-595.
41. Love RR, Korolchouk V: Tamoxifen therapy in breast cancer control worldwide. Bull World Health Organ 1993, 71:795-803.
42. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 1991, 51:3867-3873.
43. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of I κ B synthesis. Science 1995, 270:286-290.
44. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J: Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995, 270:14255-14258.
45. WAF1 and proliferating cell nuclear antigen. Curr Biol 1995, 5:275-282.
46. Koizumi M, Kamiya H, Ohtsuka E: Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene. Gene 1992, 17:179-184.
47. Besalga J, Norton L, Masui H, Papdilla A, Caplar K, Miller WH, Mendelsohn J: Antitumor effects of doxorublan in combination with anti-EGF receptor monoclonal antibodies. J Natl Cancer Inst 1993, 85:1327-1333.
48. neu expressing non-small cell lung cancer cells. Cancer Res 1996, in press.
49. Powis G, Bonjouklian R, Berggren MM, Gallegos A, Abraham R, Ashendel C, Zalkow L, Matter WF, Dodge J, Grindey G et al.: Wortmannln a potent and selective inhibitor of phosphatidylinositol-3′-kinase. Cancer Res 1994, 1:2419-2423.
50. Arcaro A, Wymann MP: Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J 1993, 96:297-301.
51. Dudley TD, Pang L, Decker SJ, Bridges AJ, Saltiel A: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995, 92:7686-7689. The first report on a MAPK pathway inhibitor. This is an interesting inhibitor as it inhibits MAPK activation by an allosteric mechanism. The compound inhibits MAPK activation by MEK by binding to MAPK on an allosteric site (AR Saltiel, personal communication).
52. Prendville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stern P, McDermott R, Potter M: A phase I study of intravenous bryostatin 1 in patients with advanced cancer. J Cell Physiol 1993, 155:301-312.
53. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Regenass U, Lydon NB: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA 1995, 92:2558-2562.
54. Anafi M, Gazit A, Zehavi A, Ben-Neriah Y, Levitzki A: Tyrphostin induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood 1993, 82:3524-3529.